Suggested remit: To appraise the clinical and cost effectiveness of serplulimab with carboplatin and etoposide within its marketing authorisation for untreated extensive-stage small-cell lung cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6346
Provisional Schedule
- Draft guidance: 1:
- 30 July 2025 - 20 August 2025
- Committee meeting: 2:
- 10 September 2025
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Newcastle NIHR TAR Team, Newcastle University
Stakeholders
- Companies sponsors
- Accord Healthcare (serplulimab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Accord Healthcare (cisplatin, carboplatin, gemcitabine)
- AstraZeneca (durvalumab)
- Consilient Health (carboplatin) - not participating
- Hospira UK (cisplatin, carboplatin, gemcitabine) - not participating
- Roche Products (atezolizumab)
- Sandoz (cisplatin) - not participating
- Sun Pharmaceuticals (gemcitabine) - not participating
- Synchrony Pharma – part of CNX Therapeutics (gemcitabine) - not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 July 2025 | Committee meeting |
| 26 November 2024 | Invitation to participate |
| 12 September 2024 - 10 October 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6346 |
| 12 September 2024 | In progress. Scoping commenced. |
| 05 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual